Brazil
Egypt
Europe
Hong Kong
Malaysia
Mexico
Morocco
Philippines
Saudi Arabia
South Africa
Taiwan
Thailand
Tunisia
Turkey
UAE
USA
Vietnam
Global HQ
GLOBAL BIOSIMILARS PORTFOLIO
Biocon Biologics has one of the deepest portfolios of biosimilars in the industry, spanning across insulin, monoclonal antibodies and conjugated recombinant proteins. Our long-term investments in R&D have yielded several molecules in diabetes, oncology, immunology, ophthalmology and bone health of which Nine have been already commercialized in markets globally.
| Therapy Area | Oncology | Immunology | Diabetes | Eye Health | Bone Health | Others |
| Approved or Commercial 10 Molecules |
bPegfilgrastim bTrastuzumab bBevacizumab |
bAdalimumab bEtanercept bUstekinumab* |
bGlargine U100 rh-Insulin bAspart |
bAflibercept | ||
| Late Stage1 2 assets |
bDenosumab bPertuzumab |
bDenosumab | ||||
| Early Stage2 8 assets |
2 undisclosed assets | 3 undisclosed assets | bGlargine U300 1 undisclosed asset |
1 undisclosed asset |
1 Clinical to BLA Review; 2 Pre-Clinical; *Approved in EU, Japan; Launched in U.S.
Our Global Scale Capabilities
Biocon Biologics offers one of the industry’s widest and deepest biosimilars portfolios, including monoclonal antibodies, insulin and insulin analogs and conjugated recombinant proteins. We have built cutting-edge R&D capabilities and created global-scale manufacturing capacities for insulins and antibodies that meet the most stringent of regulatory norms. Our commercial footprint for biosimilars stretches to over 100 countries.
Setting New Benchmarks for Worldwide Biosimilars Industry
Biocon Biologics has achieved many global ‘firsts’ and set new benchmarks for the global biosimilars industry. In July 2021, we were the first to get an interchangeable designation for our biosimilar Insulin Glargine (Semglee) from the U.S. FDA. This is a testament to the Company’s scientific excellence and robust quality comparability data.
We were also the first company to receive U.S. FDA approvals for biosimilar Trastuzumab in 2017 and biosimilar Pegfilgrastim in 2018.
Biocon Biologics and Viatris Inc. Receive Historic Approval for First Interchangeable Biosimilar Semglee@ (insulin glargine-yfgn injection) for the Treatment of Diabetes
Scientific Publications
Biocon Biologics has always valued and cherished its role in being part of a rich scientific ecosystem. BBL’s scientists are encouraged to be creative and active members of the scientific community. We are proud to feature in key scientific publications and peer-reviewed journals, thus providing scientifically accurate, fair, and well-balanced publications to the larger scientific community.
A Century of Insulins
Marking 100 years of the pivotal medical breakthrough that is saving millions of people with diabetes.
